Esther Green is the Director, Person-Centred Perspective at the Canadian Partnership Against Cancer. She is a co-investigator on research grants in the areas of: mentorship, advance practice nursing roles, patient safety, patient engagement and patient experience. She has published many articles in peer-reviewed journals and has authored chapters in nursing textbooks.
Ms. Green is a member of several cancer societies including the Canadian Association of Nurses in Oncology (CANO) and the Canadian Association of Psychosocial Oncology (CAPO). She is a member of the Sigma Theta Tau International Society of Nurses, and has served on the Lambda Pi Chapter Board. She is a past president of the Board of Directors at both CANO and CAPO. Ms. Green is also is a past member of the Board of Directors, International Society of Nurses in Cancer Care.
Areas of Expertise (8)
Lifetime Achievement Award (professional)
Canadian Association of Nurses in Oncology
Award of Excellence (professional)
Canadian Association of Psychosocial Oncology
Award of Excellence in Nursing Leadershp (professional)
Ontario Hospital Association
McMaster University: MSc, Health Sciences and Education 1991
University of Windsor: BSc, BA, Nursing and Psychology 1975
Objective: To examine oncology nurses' attitudes toward and reported use of the Edmonton Symptom Assessment System (ESAS) and to determine whether the length of work experience and presence of oncology certification are associated with their attitudes and reported usage. .
Previous systematic reviews have found limited evidence for the effectiveness of pharmacological and psychological interventions for the management of depression in patients with cancer. This paper provides the first meta-analysis of newer collaborative care interventions, which may include both types of treatment, as well as integrated delivery and follow-up. Meta-analyses of pharmacological and psychological interventions are included as a comparison.
This study summarises research- and practice-based evidence on home-based chemotherapy, and explores existing delivery models. A three-pronged investigation was conducted consisting of a literature review and synthesis of 54 papers, a review of seven home-based chemotherapy programmes spanning four countries, and two case studies within the Canadian province of Ontario. The results support the provision of home-based chemotherapy as a safe and patient-centred alternative to hospital- and outpatient-based service. This paper consolidates information on home-based chemotherapy programmes including services and drugs offered, patient eligibility criteria, patient views and experiences, delivery structures and processes, and common challenges. Fourteen recommendations are also provided for improving the delivery of chemotherapy in patients' homes by prioritising patient-centredness, provider training and teamwork, safety and quality of care, and programme management. The results of this study can be used to inform the development of an evidence-informed model for the delivery of chemotherapy and related care, such as symptom management, in patients' homes.
Ontario is Canada's largest province, with a population of 13.5 million people. Its cancer system is organized into 14 regions comprising a regional cancer program, a regional cancer center (RCC), and numerous community providers as part of their range of services. Cancer Care Ontario (CCO) is the government agency responsible for overseeing funding for the regional cancer programs and to develop and implement quality improvements and standards in the delivery of care.
In 2006, CCO launched the Provincial Palliative Care Integration Project with the goal of improving symptom management.1,2 The Edmonton Symptom Assessment System (ESAS)—a self-reported instrument measuring nine common symptoms of cancer—was selected as the standardized screening tool.3,4 In 2008, the project was expanded to become the Ontario Cancer Symptom Management Collaborative (OCSMC) with screening extended to include all patients with cancer in recognition of the heavy symptom burden that patients with cancer face.5 The goal of the OCSMC is to contribute to an excellent patient experience by improving the quality and consistency of physical and emotional symptom management throughout the cancer journey.
Chemotherapy delivery is complex, involving multiple providers across settings to deliver safe, effective care. Cancer Care Ontario initiated a provincial breakthrough series collaborative, based on methodology from the Institute for Healthcare Improvement (IHI), to improve the safe delivery of chemotherapy, from ordering through preparation and administration.
Improving symptom management is a critical component of high quality care. Cancer Care Ontario (CCO) is working to improve through a standardized approach to symptom screening and assessment that leverages electronic tools along the cancer journey.
Objective: To evaluate the efficacy of pharmacological and nonpharmacological treatments for depression in cancer populations.
The Supportive Care Guidelines Group conducted a systematic review of the published literature through June 2005. Search sources includes MEDLINE, EMBASE, CINAHL, PsycInfo, and the Cochrane Library. Comparative studies of treatments for depression in cancer patients were selected for review by two group members based on predefined criteria.
A systematic review and meta-analysis was conducted to test the hypothesis that oncology health care workers are at an increased risk of cancer, reproductive complications and acute toxic events.